||||||||||D-4517.2 SC / Ashvattha Therap Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants (clinicaltrials.gov) - Apr 28, 2022 P1, N=16, Recruiting, Sponsor: Ashvattha Therapeutics, Inc. Although D-4517.2 is renally cleared within 24 hours in animals, CNV lesion formation was suppressed for 2 weeks after a single SC in the CNV mouse model1. Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2022 --> Jun 2022